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Abstract
Genetic data are now collected frequently in clinical studies and epidemiological cohort studies.
For a large study, it may be prohibitively expensive to genotype all study subjects, especially with
the next-generation sequencing technology. Two-phase sampling, such as case-cohort and nested
case-control sampling, is cost-effective in such settings but entails considerable analysis
challenges, especially if efficient estimators are desired. A different type of missing data arises
when the investigators are interested in the haplotypes or the genetic markers that are not on the
genotyping platform used for the current study. Valid and efficient analysis of such missing data is
also interesting and challenging. This article provides an overview of these issues and outlines
some directions for future research.
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1. INTRODUCTION
Thanks to the availability of detailed genetic maps across the human genome (e.g., The
International Human Genome Sequencing Consortium, 2001; The International HapMap
Consortium, 2005) and precipitous drops in genotyping costs, there has been a worldwide
proliferation of genetic association studies, which explore population relationships between
disease phenotypes and genetic variants, particularly single nucleotide polymorphisms
(SNPs). Many of these studies survey the entire genome with high-density genotyping chips
containing several million SNPs; such studies are referred to as genome-wide association
studies (GWAS). Recent technological advances have made it possible to conduct
sequencing studies, which determine the entire DNA sequence of individual genes, all
exomes or whole genomes.
Most genetic association studies employ the case-control design, which genotypes a sample
of diseased individuals and a sample of disease-free individuals. This design is particularly
appealing for rare diseases. Cohort studies offer several advantages over case-control
studies. First, the age of onset carries more information about the etiology of a disease than
the disease status. Secondly, selection and information biases inherent in case-control
studies can usually be removed in cohort studies. Thirdly, the cohort design enables one to
investigate a wide range of diseases and related phenotypes in a single study.
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Cohort studies are major undertakings, requiring long-term follow-up of many individuals,
especially for rare diseases. Fortunately, there are a number of cohort studies that have
already been assembled for other purposes and have repositories of stored specimens that
allow the individuals to be genotyped for the genes of interest. Examples of well-established
cohorts include the Cardiovascular Health Study (Fried et al. 1991), the Women’s Health
Initiative (Johnson et al. 1999) and the Atherosclerosis Risk in Communities (ARIC) Study
(The ARIC Investigators 1989).
Despite the continuing improvement in genotyping efficiency, it is still expensive to
genotype a large cohort. A cost-effective strategy is to employ the case-cohort or nested
case-control design (Prentice, 1986; Thomas, 1977), so that only a subset of the cohort
members need to be genotyped. Such designs pose a challenging missing-data problem in
that the subjects who are not selected for genotyping have no genotype data.
A different type of missing data arises in the analysis of haplotype-disease association. A
haplotype is a specific sequence of nucleotides on the same chromosome of a subject.
Because current genotyping technologies do not separate a subject’s two homologous
chromosomes, haplotypes are not directly observed. A related form of missing data arises
when investigators are interested in untyped SNPs, i.e., the SNPs that are not even on the
genotyping chip used in the study and are thus missing on all study subjects.
In this article, we describe statistical methods for handling the aforementioned missing-data
problems. The methods are based on nonparametric maximum likelihood estimation.
Kalbfleisch and Prentice (2002) provided extensive coverage of likelihood construction for
survival data. In particular, they presented a general form of likelihood for missing covariate
data (Kalbfleisch and Prentice, 2002, p. 344). In this article, we show how to apply the
general principle of Kalbfleisch and Prentice (2002) to the two specific missing-data
problems mentioned above. We will discuss some related open problems.
2. TWO-PHASE SAMPLING
Let T denote the failure time, G denote the genetic variable, and X denote a set of
environmental factors. We specify that the hazard function of T conditional on G and X
satisfies the proportional hazards model (Cox, 1972)
where λ0(·) is an unspecified baseline hazard function, Z is a vector-function of G and X, and
θ is a set of unknown regression parameters. Under the commonly assumed additive mode
of inheritance, G pertains to the number of the “risk” allele the subject carries at the locus of
interest.
In practice, T is subject to right censoring. Let C denote the censoring time. For each T, we
observe Y and Δ, where Y = min(T, C), Δ = I(T ≤ C), and I(·) is the indicator function. For a
cohort of n subjects, the data potentially consist of (Yi, Δi, Xi, Gi) (i = 1, …, n).
For a large cohort, it may be prohibitively expensive to genotype all cohort members. A
cost-effective strategy to employ a two-phase design. In the case-cohort design (Prentice,
1986), all the cases (i.e., the subjects with Δi = 1) and a random sample of controls (i.e., the
subjects with Δi = 0) are selected for genotyping. In the nested case-control design (Thomas,
1977), a small number of controls, typically between 1 and 5, are selected for each case. In
the original case-cohort and nested case-control designs (Prentice, 1986; Thomas, 1977),
both the Gi’s and Xi’s are measured only on the selected subjects. We consider the more
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realistic scenario in which the Xi’s are available on all cohort members. We allow the
selection to depend on any aspects of the data (Yi, Δi, Xi) (i = 1, …, n). In particular, some
cases may not be selected, and the selection probabilities may depend on the Xi’s. For i = 1,
…, n, let Ri indicate, by the values 1 versus 0, whether Gi is measured or not. Then the
observed data consist of (Yi, Δi, Xi, Ri, RiGi) (i = 1, …, n).
The likelihood function takes the form
(1)
where P(·∣·) denotes conditional density functions (Kalbfleisch and Prentice, 2002, p. 344).
Under the assumption that C is independent of T and G conditional on X, P(Y, Δ∣G, X) is
proportional to
(2)
where  (Kalbfleisch and Prentice, 2002, p. 54). The likelihood function
given in (1) is not tractable if X is continuous and correlated with G. We assume that X is
independent of G or is discrete such that P(G∣X) is a discrete probability function.
Note that (1) is a nonparametric likelihood in that λ0(·) is an infinite-dimensional parameter.
To maximize (1), we let the estimator for Λ0 be a step function with jumps only at the
observed Yi with Δi = 1 and replace λ0(Y) in (2) by the jump size of Λ0(·) at Y. The
maximization can be carried out by an EM algorithm (Zeng et al., 2006). The resulting
estimator of θ is consistent, asymptotically normal, and asymptotically efficient (Zeng et al.,
2006). The limiting covariance matrix can be estimated by the profile likelihood method
(Murphy and van der Vaart, 2000).
3. HAPLOTYPES
We consider a set of SNPs that are correlated. We may have a direct interest in the
haplotypes of these SNPs or wish to use the haplotype distribution to infer the unknown
value of one SNP from the observed values of the other SNPs. Let H and G denote the
diplotype (i.e., the pair of haplotypes on the two homologous chromosomes) and genotype,
respectively. We write H = (h, h′) if the diplotype consists of h and h′, in which case G = h +
h′. Note that H cannot be determined with certainty on the basis of G if the two constituent
haplotypes differ at more than one position.
We specify that the hazard function of T conditional on X and H satisfies the proportional
hazards model
where λ0(·) is an unspecified baseline hazard function, Z(X, H) is a vector-function of X and
H, and the θ is a set of unknown regression parameters (Lin, 2004; Lin and Zeng, 2006). If
we are interested in the additive genetic effect of a risk haplotype h* and its interactions with
X, then we may specify
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If we are interested in the additive effect of a particular SNP, then we replace I(h = h*) + I(h′
= h*) by the value of (h + h′) at that SNP position.
Because H is not directly observed, it is not possible to make statistical inference without
constraining the joint distribution between the two constituent haplotypes in H. Let K be the
total number of haplotypes in the population. For k = 1, …, K, denote the kth haplotype by
hk. Define πkl = Pr(H = (hk, hl)) and πk = Pr(h = hk), k, l = 1, …, K. Under Hardy-Weinberg
equilibrium (HWE),
It possible to allow parametric departures from HWE (Lin and Zeng, 2006), but HWE is
expected to hold reasonably well in most human populations.
Assume that C is independent of T and H conditional on X and G. The likelihood takes the
form
(3)
where S(G) is the set of diplotypes that are compatible with genotype G. If X and H are
independent, then P(Xi∣H) does not depend on H and can be dropped from the likelihood
(Lin and Zeng, 2006). If X and H are not independent, we characterize their dependence
through a generalized odds ratio function (Hu et al., 2010).
To maximize the nonparametric likelihood given in (3), we treat Λ0(·) as a right-continuous
function and replace λ0(Y) with the jump size of Λ0(·) at Y. The maximization can be carried
out through EM algorithms (Lin and Zeng, 2006; Hu et al., 2010). The resulting estimator of
θ is consistent, asymptotically normal, and asymptotically efficient (Lin and Zeng, 2006; Hu
et al., 2010). The limiting covariance matrix can be estimated by using the profile likelihood
function (Murphy and van der Vaart, 2000).
When one of the SNPs in G is untyped, i.e., missing on all study subjects, the haplotype
probabilities (π1, …, πK) cannot be estimated from the study data alone. Fortunately,
external databases, such as the HapMap, can be used to estimate these probabilities. Suppose
that the external sample consists of ñ trios. For the jth trio, the genotype data consist of Gj ≡
(GFj, GMj, GCj), where GFj, GMj and GCj denote the genotypes for the father, mother and
child, respectively. Then the likelihood function for the external sample is
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where (hk, hl, hk′, hl′) ∈ S(Gj) means that (hk, hl) is compatible with GFj, (hk′, hl′) is
compatible with GMj, and (hk, hk′), (hk, hl′), (hl, hk′) or (hl, hl′) is compatible with GCj. We
multiply (3) by this likelihood and maximize the combined likelihood function. The
resulting estimator of θ is consistent, asymptotically normal, and asymptotically efficient.
4. REMARKS
We have focused on the proportional hazards model. All the results described in this article
can be extended to semiparametric linear transformation models (Lin and Zeng, 2006; Zeng
et al., 2006; Hu et al., 2010). It would be more difficult to extend to the semiparametric
accelerated failure time model (Kalbfleisch and Prentice, 2002, Ch. 7). We have assumed
that X is time-invariant. It would be challenging to allow X to be time-varying in the
likelihood approach.
There is a large body of statistical literature on case-cohort designs. Most of the estimators
are based on inverse probability weighting. The interested readers are referred to Kalbfleisch
and Prentice (2002, §11.4) and Zeng et al. (2006) for references.
In the genetics community, the prevailing approach to analyzing untyped SNPs is single
imputation (Marchini et al., 2007). Because of strong correlations among neighboring SNPs,
untyped SNPs can often be imputed with high accuracy and thus single imputation works
quite well in practice. However, the SNPs with low frequencies cannot be imputed
accurately. In general, single imputation does not yield valid tests of genetic association or
consistent estimators of genetic effects.
Case-cohort and nested case-control designs were used in several GWAS studies. Due to the
substantial drops in genotyping costs, many large cohorts have genotyped all cohort
members on GWAS chips. There is now a growing interest in next-generation sequencing.
Such technologies are much more expensive than GWAS chips. Thus, two-phase sampling
provides a cost-effective strategy to conduct sequencing studies with age-of-onset
phenotypes.
Extreme-trait sampling, which is in the same vein as two-phase cohort sampling, was
recently adopted in sequencing studies on quantitative traits. In the NHLBI Exome
Sequencing Project, subjects with the highest or lowest values of body mass index, low-
density lipoprotein or blood pressures were selected from several large cohorts for whole-
exome sequencing. In the Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) resequencing project, subjects with the highest values of several quantitative
traits were selected from three major cohorts along with a random sample. Likelihood
functions similar to (1) can be constructed for such two-phase sampling.
Case-control sampling is also a form of two-phase sampling in that the sampling is based on
the disease status. Prentice and Pyke (1979) showed that case-control sampling can be
ignored in the logistic regression analysis of case-control data. This remarkable result,
however, does not apply to two-phase sampling for survival time or continuous trait.
Furthermore, standard statistical methods cannot be used to analyze data on secondary traits,
i.e., the traits that are correlated with the one used for sampling.
Much of the recent genetic research has focused on association studies, which are
considered the first step toward the ultimate goal of personalized medicine. As genetic
research shifts to personalized medicine, survival analysis of genetic data will become more
prominent since the goal of personalized medicine is to prevent disease and prolong life and
the time to disease occurrence or death is often subject to complex censoring. Thus, we
expect survival analysis of genetic data to be a very active research area in the coming years.
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